Led by a veteran biopharma team, Facile is bringing the orally bioavailable small molecule Ebselen into a Phase 2 trial to demonstrate that this molecule, already de-risked for human safety, will be effective in treating Clostridium difficile (C diff) infections (CDI). CDI is America’s most urgent infectious disease threat according to the CDC (bit.ly/cdcTopThreats), attempts to develop new treatments have met with limited success, driving a growing global market for CDI treatments. Facile co-founder Dr. Matthew Bogyo of Stanford demonstrated Ebselen is effective in a mouse model of CDI, and published the results in Science Translational Medicine. Moreover, Ebselen had been previously evaluated in late-stage clinical trials for stroke. While efficacy was not sufficient for approval, the drug has been shown to have a favorable safety profile. Ebselen is not approved for any indication in any market. Facile will bring Ebselen into a Phase 2 proof-of-concept study in 2018 that we estimate will cost $4MM and take 1-2 years to complete. To ensure success of the program, we are working with Dr. Ciaran Kelly (Harvard) to design the trial, and with Dr. Sahil Khanna (Mayo clinic) to be Principal Investigator. Our current goal is to raise a $1MM seed to make Ebselen Phase 2-ready. Success will result in a validated asset for a disease with significant unmet need, and an opportunity for an early exit. Companies with validated Phase 2 assets for CDI have valuations from $100 to 400 MM.